| Pharmacogenetics of psoriasis: HLA‐Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker … M Talamonti, E Botti, M Galluzzo, M Teoli, G Spallone, M Bavetta, ... British Journal of Dermatology 169 (2), 458-463, 2013 | 178 | 2013 |
| Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real‐life study C Patruno, M Napolitano, G Argenziano, K Peris, M Ortoncelli, ... Journal of the European Academy of Dermatology and Venereology 35 (4), 958-964, 2021 | 78 | 2021 |
| Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation M Galluzzo, M Talamonti, C De Simone, S D’Adamio, G Moretta, ... Expert opinion on biological therapy 18 (7), 727-735, 2018 | 67 | 2018 |
| New insight into the pathogenesis of nail psoriasis and overview of treatment strategies A Ventura, M Mazzeo, R Gaziano, M Galluzzo, L Bianchi, E Campione Drug design, development and therapy, 2527-2535, 2017 | 67 | 2017 |
| Role of the HLA‐C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients M Talamonti, M Galluzzo, JM Van Den Reek, EM de Jong, JLW Lambert, ... British Journal of Dermatology 177 (2), 489-496, 2017 | 67 | 2017 |
| Italian Guidelines in diagnosis and treatment of alopecia areata A Rossi, M Muscianese, BM Piraccini, M Starace, M Carlesimo, ... Giornale Italiano di Dermatologia e Venereologia 154 (6), 609-623, 2019 | 65 | 2019 |
| Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study M Galluzzo, L Tofani, P Lombardo, A Petruzzellis, D Silvaggio, CG Egan, ... Journal of Clinical Medicine 9 (7), 2170, 2020 | 60 | 2020 |
| IL12B (p40) gene polymorphisms contribute to ustekinumab response prediction in psoriasis M Galluzzo, AN Boca, E Botti, C Potenza, G Malara, P Malagoli, S Vesa, ... Dermatology 232 (2), 230-236, 2016 | 59 | 2016 |
| Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature G Caldarola, F Pirro, A Di Stefani, M Talamonti, M Galluzzo, S D’Adamio, ... Expert opinion on biological therapy 20 (6), 665-672, 2020 | 57 | 2020 |
| Secukinumab shows high efficacy irrespective of HLA‐Cw6 status in patients with moderate‐to‐severe plaque‐type psoriasis: SUPREME study A Costanzo, L Bianchi, ML Flori, G Malara, L Stingeni, M Bartezaghi, ... British journal of dermatology 179 (5), 1072-1080, 2018 | 55 | 2018 |
| HLA-C* 06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up M Talamonti, M Galluzzo, S Chimenti, A Costanzo Journal of the American Academy of Dermatology 74 (2), 374-375, 2016 | 53 | 2016 |
| Treat-to-target approach for the management of patients with moderate-to-severe plaque psoriasis: consensus recommendations P Gisondi, M Talamonti, A Chiricozzi, S Piaserico, P Amerio, A Balato, ... Dermatology and Therapy 11, 235-252, 2021 | 47 | 2021 |
| Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study M Talamonti, M Galluzzo, A Chiricozzi, P Quaglino, G Fabbrocini, ... Expert Opinion on Biological Therapy 21 (2), 271-277, 2021 | 46 | 2021 |
| Alexithymia and plaque psoriasis: preliminary investigation in a clinical sample of 250 patients M Talamonti, M Galluzzo, S Servoli, S D'Adamio, L Bianchi Dermatology 232 (6), 648-654, 2017 | 46 | 2017 |
| Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study MS Chimenti, A Ortolan, M Lorenzin, P Triggianese, M Talamonti, L Costa, ... Clinical Rheumatology 37, 397-405, 2018 | 43 | 2018 |
| Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris A Di Stefani, M Galluzzo, M Talamonti, A Chiricozzi, A Costanzo, ... Journal of Dermatological Case Reports 7 (1), 5, 2013 | 41 | 2013 |
| Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab M Galluzzo, S D’Adamio, L Bianchi, M Talamonti Journal of Dermatological Treatment 30 (1), 40-44, 2019 | 40 | 2019 |
| Quality of life and psychological impact in patients with atopic dermatitis M Talamonti, M Galluzzo, D Silvaggio, P Lombardo, C Tartaglia, L Bianchi Journal of clinical medicine 10 (6), 1298, 2021 | 39 | 2021 |
| In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis M Galluzzo, S D’Adamio, D Silvaggio, P Lombardo, L Bianchi, ... Expert Opinion on Biological Therapy 20 (2), 173-182, 2020 | 37 | 2020 |
| Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab S Signa, E Campione, M Rusmini, S Chiesa, A Grossi, A Omenetti, ... Pediatric Rheumatology 17, 1-6, 2019 | 35 | 2019 |
Simone D'AdamioUOC Dermatologia RavennaVerified email at auslromagna.it
